SCHEMBL516632

SCHEMBL516632

CCCCOC(=O)c1ccc(OC(C)=O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.68
LMNA P02545 2/20 0.68
CYP1A2 P05177 2/20 0.68
TSHR P16473 2/20 0.68
CYP2C19 P33261 2/20 0.68
CYP2D6 P10635 1/20 0.68
MAPK1 P28482 1/20 0.68
NR1H2 P55055 1/20 0.68
RNASEL Q05823 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
CYP3A4 P08684 1/20 0.66
CYP2C9 P11712 1/20 0.66
PDE4D Q08499 1/20 0.66
HPGD P15428 2/20 0.63
RECQL P46063 1/20 0.63
STS P08842 7/20 0.61
MAPT P10636 5/20 0.58
ALDH1A1 P00352 2/20 0.58
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8197525 0.95 MAPT (0.66) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL9664878 0.95 MAPT (0.66) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL10423327 0.95 LMNA (0.62) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL9446645 0.93 LMNA (0.57) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL9650912 0.93 MAPT (0.67) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL4644691 0.92 ALDH1A1 (0.64) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL9446681 0.92 LMNA (0.56) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL7123794 0.90 LMNA (0.68) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL10344348 0.90 LMNA (0.72) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL20987320 0.89 MAPT (0.63) ESR1LMNACYP1A2TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473606-B1 Controlling transgene expression across the skin ETH ZUERICH (CH) 2016-06-29 EP disclosed
US-8653046-B2 Controlling transgene expression across the skin ETH ZURICH (CH) 2014-02-18 US disclosed
EP-2473606-A1 CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN ETH Zurich (CH) 2012-07-11 EP disclosed
US-20120029074-A1 CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN ETH ZURICH (CH) 2012-02-02 US disclosed
WO-2010115583-A1 CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN ETH ZURICH (CH) 2010-10-14 WO disclosed
EP-2239326-A1 Controlling transgene expression across the skin ETH Zurich (CH) 2010-10-13 EP disclosed
EP-0342652-B1 Thermoplastic wholly aromatic copolyimide ester and process for producing the same IDEMITSU PETROCHEMICAL CO (JP) 1995-03-08 EP disclosed
US-5003030-A Thermoplastic wholly aromatic copolyimide ester and process for producing the same IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1991-03-26 US disclosed
EP-0342652-A2 Thermoplastic wholly aromatic copolyimide ester and process for producing the same IDEMITSU PETROCHEMICAL CO. LTD. (JP) 1989-11-23 EP disclosed
US-3962314-A Oxybenzoyl dioxyarylene mono- and diesters THE CARBORUNDUM COMPANY (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029074-A1 CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN REL, CUTA, PTAR1 ESR1 2343/4885LMNA 3576/4885CYP1A2 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.